| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tumor Suppressor Protein p53 | 9 | 2023 | 85 | 3.280 |
Why?
|
| Drug Resistance, Neoplasm | 9 | 2024 | 67 | 3.210 |
Why?
|
| Proto-Oncogene Proteins c-akt | 8 | 2022 | 57 | 2.490 |
Why?
|
| Imidazoles | 7 | 2019 | 62 | 2.420 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2023 | 236 | 2.420 |
Why?
|
| Piperazines | 7 | 2019 | 82 | 2.390 |
Why?
|
| Receptors, Estrogen | 6 | 2022 | 62 | 2.320 |
Why?
|
| Autophagy | 8 | 2022 | 30 | 2.140 |
Why?
|
| Antineoplastic Agents | 9 | 2024 | 196 | 2.120 |
Why?
|
| Breast Neoplasms | 9 | 2022 | 392 | 1.780 |
Why?
|
| Cell Line, Tumor | 19 | 2024 | 244 | 1.730 |
Why?
|
| Lung Neoplasms | 4 | 2023 | 539 | 1.650 |
Why?
|
| Tamoxifen | 4 | 2022 | 30 | 1.650 |
Why?
|
| Cisplatin | 5 | 2022 | 60 | 1.340 |
Why?
|
| Apoptosis | 9 | 2019 | 196 | 1.150 |
Why?
|
| Triple Negative Breast Neoplasms | 3 | 2024 | 16 | 1.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2024 | 111 | 1.000 |
Why?
|
| Carboxypeptidases | 3 | 2022 | 8 | 0.960 |
Why?
|
| Neoplasms | 2 | 2018 | 216 | 0.960 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 3 | 2022 | 9 | 0.950 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2024 | 4 | 0.860 |
Why?
|
| Glycolysis | 3 | 2018 | 12 | 0.760 |
Why?
|
| Retinoblastoma-Like Protein p130 | 1 | 2022 | 3 | 0.730 |
Why?
|
| Humans | 37 | 2024 | 22947 | 0.730 |
Why?
|
| Signal Transduction | 8 | 2022 | 398 | 0.730 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 202 | 0.710 |
Why?
|
| Fatty Acids | 1 | 2021 | 33 | 0.700 |
Why?
|
| Proto-Oncogene Proteins c-vav | 3 | 2010 | 5 | 0.660 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2021 | 44 | 0.600 |
Why?
|
| Insulin Receptor Substrate Proteins | 2 | 2020 | 15 | 0.590 |
Why?
|
| ErbB Receptors | 3 | 2010 | 54 | 0.590 |
Why?
|
| Ketoglutarate Dehydrogenase Complex | 1 | 2018 | 3 | 0.580 |
Why?
|
| Ketoglutaric Acids | 1 | 2018 | 3 | 0.580 |
Why?
|
| Sp1 Transcription Factor | 1 | 2018 | 5 | 0.580 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 5 | 2010 | 11 | 0.570 |
Why?
|
| Ubiquitin-Protein Ligases | 4 | 2007 | 26 | 0.530 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 4 | 2019 | 34 | 0.530 |
Why?
|
| Cell Lineage | 1 | 2015 | 25 | 0.470 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2017 | 57 | 0.440 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2014 | 26 | 0.430 |
Why?
|
| Mice | 12 | 2022 | 1250 | 0.430 |
Why?
|
| Serine Endopeptidases | 1 | 2014 | 14 | 0.430 |
Why?
|
| Sirolimus | 1 | 2014 | 20 | 0.430 |
Why?
|
| Nitric Oxide | 1 | 2014 | 72 | 0.420 |
Why?
|
| Protein Kinases | 1 | 2014 | 11 | 0.420 |
Why?
|
| Enzyme Activation | 6 | 2014 | 109 | 0.410 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2004 | 33 | 0.410 |
Why?
|
| Animals | 16 | 2022 | 3295 | 0.410 |
Why?
|
| MCF-7 Cells | 3 | 2021 | 15 | 0.400 |
Why?
|
| cdc42 GTP-Binding Protein | 2 | 2010 | 7 | 0.400 |
Why?
|
| rac1 GTP-Binding Protein | 2 | 2010 | 13 | 0.400 |
Why?
|
| Mammary Glands, Human | 2 | 2009 | 7 | 0.390 |
Why?
|
| rhoA GTP-Binding Protein | 2 | 2009 | 9 | 0.390 |
Why?
|
| Receptors, Glycine | 2 | 2009 | 2 | 0.380 |
Why?
|
| Paclitaxel | 2 | 2022 | 49 | 0.380 |
Why?
|
| RNA, Small Interfering | 3 | 2019 | 76 | 0.370 |
Why?
|
| Epithelial Cells | 2 | 2010 | 70 | 0.340 |
Why?
|
| Cytotoxins | 1 | 2010 | 1 | 0.340 |
Why?
|
| Adherens Junctions | 1 | 2010 | 3 | 0.340 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 52 | 0.330 |
Why?
|
| Cell Movement | 1 | 2010 | 77 | 0.330 |
Why?
|
| Cell Proliferation | 1 | 2010 | 163 | 0.320 |
Why?
|
| Morphogenesis | 1 | 2009 | 8 | 0.310 |
Why?
|
| Methylation | 2 | 2019 | 10 | 0.300 |
Why?
|
| Osteosarcoma | 3 | 2018 | 36 | 0.300 |
Why?
|
| Histones | 2 | 2019 | 28 | 0.300 |
Why?
|
| Cell Survival | 4 | 2019 | 99 | 0.300 |
Why?
|
| Caffeine | 1 | 2009 | 53 | 0.300 |
Why?
|
| Ubiquitin | 5 | 2007 | 29 | 0.300 |
Why?
|
| Cell Cycle Checkpoints | 2 | 2022 | 7 | 0.290 |
Why?
|
| Kidney | 1 | 2009 | 142 | 0.280 |
Why?
|
| Female | 11 | 2024 | 12954 | 0.280 |
Why?
|
| Bone Neoplasms | 3 | 2018 | 118 | 0.280 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 2 | 2018 | 9 | 0.270 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2021 | 19 | 0.260 |
Why?
|
| Checkpoint Kinase 1 | 2 | 2019 | 7 | 0.260 |
Why?
|
| Phosphorylation | 6 | 2016 | 131 | 0.260 |
Why?
|
| RNA Interference | 2 | 2019 | 36 | 0.250 |
Why?
|
| Retroviridae Proteins, Oncogenic | 2 | 2003 | 2 | 0.250 |
Why?
|
| Cell Line | 6 | 2013 | 250 | 0.250 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2005 | 17 | 0.250 |
Why?
|
| Gene Knockdown Techniques | 2 | 2018 | 41 | 0.250 |
Why?
|
| Mitochondria | 2 | 2005 | 55 | 0.250 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2016 | 10 | 0.230 |
Why?
|
| Oxygen | 2 | 2015 | 56 | 0.220 |
Why?
|
| Nitrogen | 1 | 2004 | 4 | 0.220 |
Why?
|
| Soil | 1 | 2004 | 6 | 0.220 |
Why?
|
| Receptors, Antigen | 1 | 2004 | 1 | 0.220 |
Why?
|
| Biomarkers, Tumor | 2 | 2024 | 200 | 0.220 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2024 | 2 | 0.220 |
Why?
|
| Trastuzumab | 2 | 2022 | 26 | 0.210 |
Why?
|
| Interleukin-6 | 1 | 2024 | 70 | 0.210 |
Why?
|
| Histone Deacetylase 1 | 1 | 2023 | 3 | 0.210 |
Why?
|
| Benzamides | 1 | 2023 | 12 | 0.210 |
Why?
|
| Retinoblastoma Protein | 1 | 2023 | 11 | 0.210 |
Why?
|
| Lysosomes | 1 | 2003 | 20 | 0.200 |
Why?
|
| Histone Demethylases | 1 | 2022 | 3 | 0.200 |
Why?
|
| Lysine | 1 | 2022 | 14 | 0.200 |
Why?
|
| Mitochondrial Swelling | 1 | 2002 | 1 | 0.190 |
Why?
|
| Cadherins | 1 | 2022 | 30 | 0.190 |
Why?
|
| Estrogen Receptor alpha | 1 | 2022 | 15 | 0.190 |
Why?
|
| Antigens, CD | 1 | 2022 | 49 | 0.190 |
Why?
|
| CD27 Ligand | 1 | 2022 | 2 | 0.190 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2022 | 3 | 0.190 |
Why?
|
| Nanoparticles | 1 | 2022 | 10 | 0.190 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2022 | 15 | 0.190 |
Why?
|
| Aurora Kinase B | 1 | 2022 | 3 | 0.180 |
Why?
|
| Aurora Kinase A | 1 | 2022 | 4 | 0.180 |
Why?
|
| Macrophages | 1 | 2002 | 89 | 0.180 |
Why?
|
| Glioblastoma | 1 | 2022 | 9 | 0.180 |
Why?
|
| Oxidation-Reduction | 1 | 2021 | 62 | 0.180 |
Why?
|
| Brain Neoplasms | 1 | 2022 | 71 | 0.170 |
Why?
|
| Receptor, ErbB-2 | 3 | 2022 | 52 | 0.160 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2017 | 21 | 0.160 |
Why?
|
| Autophagy-Related Proteins | 1 | 2019 | 4 | 0.150 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2019 | 5 | 0.150 |
Why?
|
| A549 Cells | 1 | 2018 | 10 | 0.150 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2018 | 3 | 0.140 |
Why?
|
| Mutation | 4 | 2010 | 328 | 0.140 |
Why?
|
| Adenosine | 1 | 2018 | 8 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2018 | 18 | 0.140 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2017 | 13 | 0.140 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2009 | 30 | 0.140 |
Why?
|
| Receptors, Somatomedin | 1 | 2017 | 5 | 0.130 |
Why?
|
| Phospholipase C gamma | 2 | 2007 | 6 | 0.130 |
Why?
|
| Epidermal Growth Factor | 2 | 2010 | 26 | 0.130 |
Why?
|
| Loss of Heterozygosity | 1 | 2016 | 6 | 0.120 |
Why?
|
| DNA Mismatch Repair | 1 | 2016 | 10 | 0.120 |
Why?
|
| Biological Assay | 1 | 2016 | 7 | 0.120 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2007 | 17 | 0.120 |
Why?
|
| Macrolides | 1 | 2015 | 6 | 0.120 |
Why?
|
| Caspase 8 | 1 | 2015 | 10 | 0.120 |
Why?
|
| Superoxides | 1 | 2015 | 23 | 0.120 |
Why?
|
| Chloroquine | 1 | 2015 | 7 | 0.120 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2015 | 22 | 0.120 |
Why?
|
| Cellular Senescence | 1 | 2015 | 15 | 0.120 |
Why?
|
| Microscopy, Electron | 1 | 2015 | 59 | 0.120 |
Why?
|
| Microscopy, Confocal | 1 | 2015 | 80 | 0.120 |
Why?
|
| Flow Cytometry | 1 | 2015 | 102 | 0.120 |
Why?
|
| DNA Methylation | 1 | 2016 | 129 | 0.110 |
Why?
|
| Phagosomes | 1 | 2014 | 2 | 0.110 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2014 | 15 | 0.110 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2014 | 10 | 0.110 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2014 | 33 | 0.110 |
Why?
|
| DNA Primers | 1 | 2014 | 49 | 0.110 |
Why?
|
| Colorectal Neoplasms | 1 | 2016 | 106 | 0.110 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 35 | 0.110 |
Why?
|
| Base Sequence | 1 | 2014 | 101 | 0.110 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2014 | 62 | 0.110 |
Why?
|
| Models, Biological | 1 | 2016 | 303 | 0.110 |
Why?
|
| Gene Expression Regulation | 2 | 2007 | 232 | 0.110 |
Why?
|
| DNA Damage | 1 | 2014 | 25 | 0.100 |
Why?
|
| Transfection | 3 | 2020 | 117 | 0.100 |
Why?
|
| Membrane Potentials | 2 | 2005 | 166 | 0.100 |
Why?
|
| Cell Adhesion | 2 | 2010 | 30 | 0.100 |
Why?
|
| Aniline Compounds | 1 | 2013 | 29 | 0.100 |
Why?
|
| Triazoles | 1 | 2013 | 28 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2011 | 315 | 0.090 |
Why?
|
| Triterpenes | 1 | 2011 | 1 | 0.090 |
Why?
|
| Estrogen Antagonists | 1 | 2010 | 3 | 0.080 |
Why?
|
| src-Family Kinases | 3 | 2007 | 6 | 0.080 |
Why?
|
| Ubiquitination | 1 | 2010 | 14 | 0.080 |
Why?
|
| Protein Transport | 1 | 2010 | 29 | 0.080 |
Why?
|
| Actins | 1 | 2010 | 35 | 0.080 |
Why?
|
| Cytoskeleton | 1 | 2010 | 33 | 0.080 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 147 | 0.080 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 185 | 0.080 |
Why?
|
| Cell Line, Transformed | 1 | 2009 | 13 | 0.080 |
Why?
|
| Mice, Nude | 3 | 2020 | 25 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2011 | 240 | 0.080 |
Why?
|
| Precancerous Conditions | 1 | 2009 | 25 | 0.070 |
Why?
|
| Urodela | 1 | 2008 | 1 | 0.070 |
Why?
|
| Retinal Ganglion Cells | 1 | 2008 | 2 | 0.070 |
Why?
|
| Glycine | 1 | 2008 | 7 | 0.070 |
Why?
|
| Synaptic Transmission | 1 | 2008 | 20 | 0.070 |
Why?
|
| Neural Inhibition | 1 | 2008 | 8 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2013 | 284 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2022 | 21 | 0.070 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2007 | 4 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2007 | 9 | 0.070 |
Why?
|
| Neovascularization, Physiologic | 1 | 2007 | 23 | 0.060 |
Why?
|
| Oncogene Protein v-cbl | 2 | 2003 | 2 | 0.060 |
Why?
|
| Necrosis | 2 | 2005 | 24 | 0.060 |
Why?
|
| Cells, Cultured | 2 | 2008 | 468 | 0.060 |
Why?
|
| Macrophages, Alveolar | 1 | 2005 | 3 | 0.060 |
Why?
|
| Plant Development | 1 | 2004 | 3 | 0.060 |
Why?
|
| Drug Synergism | 2 | 2017 | 38 | 0.050 |
Why?
|
| Immune Tolerance | 1 | 2004 | 12 | 0.050 |
Why?
|
| China | 1 | 2004 | 45 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2004 | 16 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2004 | 125 | 0.050 |
Why?
|
| Oncogene Proteins | 1 | 2003 | 6 | 0.050 |
Why?
|
| Mice, Knockout | 1 | 2004 | 282 | 0.050 |
Why?
|
| CHO Cells | 1 | 2003 | 11 | 0.050 |
Why?
|
| Cricetinae | 1 | 2003 | 34 | 0.050 |
Why?
|
| Embryo, Mammalian | 1 | 2003 | 24 | 0.050 |
Why?
|
| Endosomes | 1 | 2003 | 8 | 0.050 |
Why?
|
| Endocytosis | 1 | 2003 | 16 | 0.050 |
Why?
|
| Temperature | 1 | 2003 | 58 | 0.050 |
Why?
|
| Fibroblasts | 1 | 2003 | 50 | 0.050 |
Why?
|
| Blotting, Western | 1 | 2003 | 131 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2003 | 89 | 0.050 |
Why?
|
| Ionophores | 1 | 2002 | 2 | 0.050 |
Why?
|
| Calcimycin | 1 | 2002 | 4 | 0.050 |
Why?
|
| Ruthenium Red | 1 | 2002 | 7 | 0.050 |
Why?
|
| Caspase Inhibitors | 1 | 2002 | 5 | 0.050 |
Why?
|
| Cytochrome c Group | 1 | 2002 | 4 | 0.050 |
Why?
|
| Blood Bactericidal Activity | 1 | 2002 | 4 | 0.050 |
Why?
|
| Intracellular Membranes | 1 | 2002 | 20 | 0.050 |
Why?
|
| Caspases | 1 | 2002 | 22 | 0.050 |
Why?
|
| Calcium-Binding Proteins | 1 | 2002 | 22 | 0.050 |
Why?
|
| Caspase 9 | 1 | 2022 | 8 | 0.050 |
Why?
|
| Caspase 3 | 1 | 2022 | 17 | 0.050 |
Why?
|
| Ceramides | 1 | 2022 | 14 | 0.050 |
Why?
|
| Permeability | 1 | 2002 | 94 | 0.050 |
Why?
|
| Gene Expression | 1 | 2003 | 178 | 0.050 |
Why?
|
| Calcium Channels | 1 | 2002 | 106 | 0.050 |
Why?
|
| Molecular Docking Simulation | 1 | 2022 | 2 | 0.050 |
Why?
|
| Genistein | 1 | 2022 | 5 | 0.050 |
Why?
|
| Protein Binding | 3 | 2007 | 114 | 0.040 |
Why?
|
| Structure-Activity Relationship | 2 | 2013 | 34 | 0.040 |
Why?
|
| Luciferases | 2 | 2013 | 25 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 523 | 0.030 |
Why?
|
| Pyrazines | 1 | 2017 | 12 | 0.030 |
Why?
|
| Reproductive History | 1 | 2017 | 1 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2017 | 26 | 0.030 |
Why?
|
| Receptor Cross-Talk | 1 | 2016 | 7 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 219 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2017 | 102 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 481 | 0.030 |
Why?
|
| Tyrosine | 2 | 2007 | 22 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 2 | 2007 | 60 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2016 | 173 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2017 | 548 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2013 | 11 | 0.030 |
Why?
|
| Biological Availability | 1 | 2013 | 16 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2013 | 22 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2013 | 97 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2013 | 97 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2013 | 315 | 0.020 |
Why?
|
| Male | 2 | 2020 | 12458 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 1651 | 0.020 |
Why?
|
| Rats | 1 | 2013 | 626 | 0.020 |
Why?
|
| Risk Factors | 1 | 2017 | 1970 | 0.020 |
Why?
|
| Pentacyclic Triterpenes | 1 | 2011 | 1 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2011 | 5 | 0.020 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2011 | 4 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2011 | 23 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2011 | 26 | 0.020 |
Why?
|
| Quinazolines | 1 | 2011 | 17 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2011 | 39 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2011 | 83 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 164 | 0.020 |
Why?
|
| rho-Associated Kinases | 1 | 2009 | 4 | 0.020 |
Why?
|
| Telomerase | 1 | 2009 | 8 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2009 | 46 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 2009 | 47 | 0.020 |
Why?
|
| Retina | 1 | 2008 | 8 | 0.020 |
Why?
|
| Ligands | 1 | 2007 | 37 | 0.020 |
Why?
|
| Laminin | 1 | 2007 | 5 | 0.020 |
Why?
|
| Binding Sites | 1 | 2007 | 68 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2007 | 6 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2007 | 31 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2007 | 17 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2007 | 23 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2007 | 125 | 0.020 |
Why?
|
| Collagen | 1 | 2007 | 81 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 112 | 0.020 |
Why?
|
| Proteoglycans | 1 | 2007 | 120 | 0.020 |
Why?
|
| Wound Healing | 1 | 2007 | 108 | 0.020 |
Why?
|
| Adult | 1 | 2017 | 6923 | 0.010 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2005 | 1 | 0.010 |
Why?
|
| Cytochromes c | 1 | 2005 | 11 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2005 | 21 | 0.010 |
Why?
|
| Cyclosporine | 1 | 2005 | 12 | 0.010 |
Why?
|
| Middle Aged | 1 | 2017 | 7910 | 0.010 |
Why?
|
| Molecular Conformation | 1 | 2004 | 10 | 0.010 |
Why?
|
| Vanadates | 1 | 2003 | 3 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 2003 | 8 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2003 | 10 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 24 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2003 | 54 | 0.010 |
Why?
|
| Plasmids | 1 | 2003 | 42 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2003 | 31 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2003 | 173 | 0.010 |
Why?
|
| Time Factors | 1 | 2003 | 1262 | 0.010 |
Why?
|